Skip to main content
Clinical Trials/NCT01501565
NCT01501565CompletedPhase 4

Ultrasound-guided Analgesic Transverse Abdominal Plain Blockade in the Multimodal Pain Management for Laparoscopic Urological Surgery. Analgesic Efficacy Assessment.

Fundacio Puigvert2 sites in 1 country141 target enrollmentStarted: December 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
141
Locations
2
Primary Endpoint
Pain level

Study Overview

Brief Summary

The purpose of this study is to compare pain level (according to numerical score)at 4, 8, 12 and 24 postoperative hours between patients under transverse abdominal plain blockade (TAP) and patients under conventional analgesia. Also the opioid consumption is assessed.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • > 18 yrs.
  • Patients undergo laparoscopic urologic surgery
  • Physical status ASA < 3
  • Surgical procedure without complications
  • Signed informed consent

Exclusion Criteria

  • Allergy to bupivacaine chlorhydrate
  • Patients with chronic pain treatment
  • Alcoholism
  • Decompensated hepatic disease
  • Coagulation disorders
  • BMI > 35
  • Patient involved in another clinical trial

Outcomes

Primary Outcomes

Pain level

Time Frame: Change in pain from admittance to 24 hours postoperatively

Pain is assessed by numerical scale (0 to 10) where 0 is no pain and 10 is the most intense pain possible. Pain will be assessed at 4, 6 , 8, 12 and 24 hours.

Secondary Outcomes

  • Analgesic consumption as a rescue therapy(within 24 postoperative hours)
  • Incidence of postoperative nausea and vomiting (PONV) related to therapy(within 24 postoperative hours)
  • Incidence of urethral/bladder spasm(within 24 postoperative hours)
  • Assessment of oral intake tolerance(within 24 postoperative hours)
  • Patient satisfaction(within 24 postoperative hours)

Investigators

Sponsor
Fundacio Puigvert
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Juan Francisco Mayoral Farre

Principal Investigator

Fundacio Puigvert

Study Sites (2)

Loading locations...

Similar Trials